Lauoria Pharmaceuticals’ consolidated subsidiary, FIMEKSU, has received a patent grant in the United States for an IRAK-M protein degradation inducer. By strengthening research and development and intellectual property, the company aims to enhance long-term corporate value.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4579","jir_company_name":"Lauoria Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4579-20260730-01.pdf","jir_short_summary":"Lauoria Pharmaceuticals' consolidated subsidiary, FIMEKSU, has received a patent grant in the United States for an IRAK-M protein degradation inducer. By strengthening research and development and intellectual property, the company aims to enhance long-term corporate value.","jir_summary":"### Overview of Patent Grant\nLauoria Pharmaceuticals' consolidated subsidiary, FIMEKSU, has received a patent grant in the United States for an IRAK-M protein degradation inducer. This compound is involved in cancer immune suppression and is expected to activate immune responses. Through further research and development and expanding intellectual property, the company aims to enhance long-term corporate value. This patent grant follows previous grants in Japan and Europe, strengthening patent rights in key markets. The impact on the consolidated performance in 2026 is minimal, but this represents an important intellectual property for future commercialization.\n\n### Future Outlook and Corporate Activities\nFIMEKSU continues to advance drug discovery research utilizing RaPPIDSTM technology, progressing pipeline research and development, and commercialization efforts. The US patent grant enhances intellectual property rights for compounds including FIM-001, supporting long-term business expansion and partnership development. The company will continue to pursue domestic and international patent examinations, leveraging its drug discovery platform to accelerate new drug development.","jir_financial_highlights":"Patent grant country: United States (Unknown)\nTarget compound group: IRAK-M protein degradation inducer (cyclic compound) (Unknown)\nImpact on FY 2026 performance: None (Unknown)","jir_category":"","jir_hashtags":"#LauoriaPharmaceuticals, #PatentGrant, #JapaneseStocks","jir_key_figures":"Patent grant country: United States\nTarget compound group: IRAK-M protein degradation inducer\nImpact on FY 2026 performance: None","jir_meta_title":"\u3010Lauoria Pharmaceuticals\u3011Strengthening of Intellectual Property Rights through US Patent Grant | July 2026","jir_meta_description":"Lauoria Pharmaceuticals' subsidiary FIMEKSU has received a US patent grant for an IRAK-M protein degradation inducer. This supports long-term research and development and enhances corporate value.","jir_og_title":"\u3010Lauoria Pharmaceuticals\u3011Strengthening of Intellectual Property Rights through US Patent Grant | July 2026","jir_og_description":"Lauoria Pharmaceuticals' subsidiary has obtained a patent grant in the US. Expect long-term research development and a boost in corporate value; important news reflecting progress.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57587,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90550","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n